Hydrocortisone plus fludrocortisone for adults with septic shock.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Septic shock is characterized by dysregulation of the host response to infection, with circulatory, cellular, and metabolic abnormalities. We hypothesized that therapy with hydrocortisone plus fludrocortisone or with drotrecogin alfa (activated), which can modulate the host response, would improve the clinical outcomes of patients with septic shock. METHODS: In this multicenter, double-blind, randomized trial with a 2-by-2 factorial design, we evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (activated), the combination of the three drugs, or their respective placebos. The primary outcome was 90-day all-cause mortality. Secondary outcomes included mortality at intensive care unit (ICU) discharge and hospital discharge and at day 28 and day 180 and the number of days alive and free of vasopressors, mechanical ventilation, or organ failure. After drotrecogin alfa (activated) was withdrawn from the market, the trial continued with a two-group parallel design. The analysis compared patients who received hydrocortisone plus fludrocortisone with those who did not (placebo group). RESULTS: Among the 1241 patients included in the trial, the 90-day mortality was 43.0% (264 of 614 patients) in the hydrocortisone-plus-fludrocortisone group and 49.1% (308 of 627 patients) in the placebo group (P=0.03). The relative risk of death in the hydrocortisone-plus-fludrocortisone group was 0.88 (95% confidence interval, 0.78 to 0.99). Mortality was significantly lower in the hydrocortisone-plus-fludrocortisone group than in the placebo group at ICU discharge (35.4% vs. 41.0%, P=0.04), hospital discharge (39.0% vs. 45.3%, P=0.02), and day 180 (46.6% vs. 52.5%, P=0.04) but not at day 28 (33.7% and 38.9%, respectively; P=0.06). The number of vasopressor-free days to day 28 was significantly higher in the hydrocortisone-plus-fludrocortisone group than in the placebo group (17 vs. 15 days, P<0.001), as was the number of organ-failure-free days (14 vs. 12 days, P=0.003). The number of ventilator-free days was similar in the two groups (11 days in the hydrocortisone-plus-fludrocortisone group and 10 in the placebo group, P=0.07). The rate of serious adverse events did not differ significantly between the two groups, but hyperglycemia was more common in hydrocortisone-plus-fludrocortisone group. CONCLUSIONS: In this trial involving patients with septic shock, 90-day all-cause mortality was lower among those who received hydrocortisone plus fludrocortisone than among those who received placebo. (Funded by Programme Hospitalier de Recherche Clinique 2007 of the French Ministry of Social Affairs and Health; APROCCHSS ClinicalTrials.gov number, NCT00625209 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the ADRENAL [479] study, hydrocortisone was administered for a maximum of seven days or until ICU discharge or death; in APROCCHSS [478] hydrocortisone was administered for seven days; in VANISH [354] 200 mg of hydrocortisone was administered daily for 5 days and then tapered over further 6 days.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“In APROCCHSS [478] the dose of vasopressor was ≥ 0.25 µg/kg/min or ≥ 1 mg/h of norepinephrine or epinephrine, or any other vasopressor for at least 6 h to maintain a MAP ≥ 65 mmHg.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“Since then, three large RCTs have been published [354, 478, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Self-citationDellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Self-citationSurviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citationVincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
Self-citationShankar-Hari, M., Phillips, G. S., Levy, M. L., Seymour, C. W., Liu, V. X., Deutschman, C. S., Angus, D. C., Rubenfeld, G. D., Singer, M., & for the Sepsis Definitions Task Force (2016) · JAMA · doi:10.1001/jama.2016.0289 · Cited by 2,424
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Self-citationAnnane, D., Bellissant, E., & Cavaillon, J.-M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17667-8 · Cited by 1,213
Self-citationAnnane, D., Vignon, P., Renault, A., Bollaert, P.-E., Charpentier, C., Martin, C., Troché, G., Ricard, J.-D., Nitenberg, G., Papazian, L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61344-0 · Cited by 567
Self-citationCognitive decline after sepsis.
Annane, D., & Sharshar, T. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70246-2 · Cited by 290
Self-citation
Research works printed but not linked: 1
- Guide “100 recommandations pour la surveillance et la préventions des infections nosocomiales.” Bulletin Epidémiologique Hebdomadaire. No. 48. November 30 1992 (http://invs.santepubliquefrance.fr/beh/1992/48/index.html).
Cited by
Items 401–500 of 968
Decreased maximal cortisol secretion rate in patients with cirrhosis: Relation to disease severity
Lovato, C. M., Thévenot, T., Borot, S., Martino, V. D., Qualls, C., Urban, F. K., & Dorin, R. I. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100277 · Cited by 12
Staging and Personalized Intervention for Infection and Sepsis
Beckmann, N., Salyer, C. E., Crisologo, P. A., Nomellini, V., & Caldwell, C. C. (2020) · Surgical Infections · doi:10.1089/sur.2019.363 · Cited by 13
Association between eosinophil count and prognosis in chronic obstructive pulmonary disease patients
Hsu, W., Shiau, B.-W., Lai, C.-C., & Liao, K. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1525709 · Cited by 10
“To ensure specificity and accuracy, standardized medical coding systems, such as the International Classification of Diseases, Tenth Revision, Systematized Nomenclature of Medicine, Current Procedural Terminology, and RxNorm codes, were used (9, 10).”
Evidence-Based Management of the Critically Ill Adult With SARS-CoV-2 Infection
Chivukula, R. R., Maley, J. H., Dudzinski, D. M., Hibbert, K. A., & Hardin, C. C. (2020) · Journal of Intensive Care Medicine · doi:10.1177/0885066620969132 · Cited by 12
Understanding purpura fulminans in adult patients
Contou, D., Urbina, T., & de Prost, N. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06580-2 · Cited by 10
“Historically described in meningococcal sepsis [13], absolute adrenal insufficiency resulting from bilateral adrenal hemorrhagic necrosis (the so-called Waterhouse–Friderichsen syndrome) may argue for systematic supplementation with both glucocorticoids and mineralocorticoids [22].”
BackgroundZang, X., Chen, S., Zhang, L., & Zhai, Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.964062 · Cited by 10
“However, the use of low-dose hydrocortisone (<400 mg/day) will shorten the reversal time of shock, and the incidence of complications caused by steroids is relatively low (31, 32).”
BackgroundRecent trends in septic shock management: a narrative review of current evidence and recommendations
Nofal, M. A., Shitawi, J., Altarawneh, H. B., Alrosan, S., Alqaisi, Y., Al-Harazneh, A.-M., Alamaren, A. M., & Abu‐Jeyyab, M. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002048 · Cited by 11
The ACTH test fails to diagnose adrenal insufficiency and augments cytokine production in sepsis
Hao, D., Wang, Q., Ito, M., Xue, J., Guo, L., Huang, B., Mineo, C., Shaul, P. W., & Li, X. (2025) · JCI Insight · doi:10.1172/jci.insight.187487 · Cited by 10
“In contrast, the APROCCHSS trial found an improved survival rate in septic patients treated with GCs, regardless of RAI status as determined by the ACTH stimulation test (19).”
Steroids and Sepsis: the Debate Continues
Ramanan, M., Cohen, J., & Venkatesh, B. (2019) · International Anesthesiology Clinics · doi:10.1097/aia.0000000000000220 · Cited by 16
Habr, B., Saliba, Y., Hajal, J., Smayra, V., Riachy, M. A., & Farès, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118366 · Cited by 10
Xiao, L., Niu, L., Xu, X., Zhao, Y., Yue, L., Liu, X., & Li, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.830030 · Cited by 10
Labib, H. A., Hassan, A. I., Kamaly, A. M., Wahba, S. S., & Ammar, M. A. (2022) · Ain-Shams Journal of Anaesthesiology · doi:10.1186/s42077-022-00259-6 · Cited by 13
“Adding fludrocortisone to the commonly used hydrocortisone regimen may account for the positive results, but further studies are needed to confirm this (Lee & Bainum, 2017; Annane et al., 2018).”
ResultSteroids in the acutely ill: Evolving recommendations and practice
Pastores, S. M. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89gr.22002 · Cited by 10
Vaidie, J., Péju, E., Jandeaux, L.-M., Lesouhaitier, M., Lachérade, J.-C., Guillon, A., Wittebole, X., Asfar, P., Evrard, B., Daix, T., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04626-z · Cited by 10
Self-citationRamsay, S. D., Nenke, M. A., Meyer, E. J., Torpy, D. J., & Young, R. L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1508848 · Cited by 9
Wu, W., Li, Y., Zhang, Y., Chen, X., Zhang, C., Qu, X., Zhang, Z., Zhang, R., & Peng, Z. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02520-x · Cited by 9
“The severity of AP was assessed using the BISAP score, harmless acute pancreatitis score (HAPS) [11], and SOFA score [12].”
Sepsis Endotypes Defined by Lymphocyte Thresholds and Inflammation Inform Precision Immunomodulation
Sun, Z., Li, L., Gao, W., Gao, H., Guo, L., & Peng, Z. (2026) · MedComm · doi:10.1002/mco2.70561 · Cited by 12
“…with Septic Shock (ADRENAL) found no mortality benefit with hydrocortisone in unselected patients [ 13 ], whereas the Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial demonstrated significant mortality reduction with combination corticosteroid therapy [ 14 ].”
Renaissance of glucocorticoids in critical care in the era of COVID-19: ten urging questions
Winkler, M. S., Osuchowski, M. F., Payen, D. M., Torres, A., Dickel, S., & Skirecki, T. (2022) · Critical Care · doi:10.1186/s13054-022-04185-9 · Cited by 10
“the APROCCHSS trial [16] among others, while some other large RCTs showed conflicting results including elevated mortality [17].”
ResultEmerging concepts in the care of patients with cirrhosis and septic shock
Jiménez, J. V., García–Tsao, G., & Saffo, S. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i4.497 · Cited by 12
Advancements in the pharmacological management of sepsis in the elderly
Psarrakis, C., & Giamarellos‐Bourboulis, E. J. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2213828 · Cited by 9
Should we initiate vasopressors earlier in patients with septic shock: A mini systemic review
Zhou, H.-X., Yang, C.-F., Wang, H.-Y., Teng, Y., & He, H. (2023) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v12.i4.204 · Cited by 11
Zhan, Z., Lian, Z., & Bai, H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0308557 · Cited by 9
Kikutani, K., Nishikimi, M., Ohshimo, S., & Shime, N. (2025) · Resuscitation · doi:10.1016/j.resuscitation.2024.110487 · Cited by 9
Hämodynamische Stabilisierung des septischen Patienten in der Notaufnahme
Schmoch, T., Bernhard, M. H., Siegler, B. H., Brenner, T., & Weigand, M. A. (2018) · Notfall + Rettungsmedizin · doi:10.1007/s10049-018-0515-7 · Cited by 9
Foushee, J. A., Meredith, P., Fox, L. M., & Wilder, A. G. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa118 · Cited by 9
What Is the Role of Steroids for Septic Shock in 2021?
Nedel, W. L., Lisboa, T. C., & Salluh, J. I. (2021) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1733900 · Cited by 9
Antibiotic Combination Therapy for Severe Scrub Typhus: Is It Necessary?
Chung, M., Lee, J. S., & Im, J. H. (2023) · Infection and Chemotherapy · doi:10.3947/ic.2023.0055 · Cited by 9
Non-antibiotic therapies for sepsis: an update
Vincent, J., & Mongkolpun, W. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2019.1581606 · Cited by 9
GILZ in sepsis: “Poor is the pupil who does not surpass his master”
Vandewalle, J., & Libert, C. (2020) · European Journal of Immunology · doi:10.1002/eji.202048582 · Cited by 11
Donovan, K., Shah, A., Day, J., & McKechnie, S. (2021) · Anaesthesia · doi:10.1111/anae.15369 · Cited by 11
“[65] published the results of a double blind, placebo controlled, multicentre randomised controlled trial (APROCCHSS), with a two-by-two factorial design, to investigate the role of recombinant activated protein C and corticosteroids (hydrocortisone plus fludrocortisone) in the treatment of patients with septic shock.”
BackgroundMethodInfluentialFalse-positive and false-negative risks for individual multicentre trials in critical care
Sidebotham, D. A., & Barlow, C. J. (2022) · BJA Open · doi:10.1016/j.bjao.2022.100003 · Cited by 10
“6%.(12,15,16) One trial by Ferguson and colleagues,(17) which compared high-frequency oscillation ventilation with conventional ventilation in patients with severe ARDS, provided moderate evidence in favour of the alternative hypothesis (BF1:0 5.”
BackgroundResultAdjunctive Corticosteroid Treatment in Septic Shock
Cohen, J., & Venkatesh, B. (2019) · Anesthesiology · doi:10.1097/aln.0000000000002604 · Cited by 11
Zhu, L., Zeng, J., Li, H., Li, K., & Chen, X. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03679-w · Cited by 8
Cao, L., Xiang, Y., Wu, Z., Chen, Q., Chen, F., Gui-ying, Y., & Li, H. (2025) · BMC Anesthesiology · doi:10.1186/s12871-025-03196-7 · Cited by 11
Shen, Y., Zhang, W. M., Lin, K., Zheng, P., Liu, X., Weng, J., & Ye, Y. (2026) · Critical Care · doi:10.1186/s13054-026-06059-w · Cited by 10
Low-dose corticosteroids in septic shock: Has the pendulum shifted?
Lemieux, S. M., & Levine, A. R. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz017 · Cited by 8
Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review
Kröker, A., & Tirzīte, M. (2021) · Respiratory Research · doi:10.1186/s12931-021-01885-8 · Cited by 8
Mahmoud, J., Bovy, M. A., Heming, N., & Annane, D. (2025) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2025.08.006 · Cited by 8
Self-citationThe critical care literature 2023
Winters, M. E., Hu, K. M., Martinez, J. P., Mallemat, H. A., & Brady, W. J. (2024) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2024.08.010 · Cited by 8
Song, B., Zheng, X., Fu, K., & Liu, C. (2024) · Medicine · doi:10.1097/md.0000000000040635 · Cited by 8
Can NLRP3 inhibitors improve on dexamethasone for the treatment of COVID-19?
Hooftman, A., & O'Neill, L. A. J. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100048 · Cited by 8
Sepsis 2018: Bangkok, Thailand. 1-3 October 2018
(2018) · Intensive Care Medicine Experimental · doi:10.1186/s40635-018-0196-z · Cited by 9
Feng, F., Yang, H., Yang, W., Li, M., & Chen, Y. (2023) · Open Medicine · doi:10.1515/med-2023-0637 · Cited by 8
The Timing of Initiating Hydrocortisone and Long-term Mortality in Septic Shock
Zhang, L., Gu, W., Huang, T., Lyu, J., & Yin, H. (2023) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006516 · Cited by 9
A Review of Current Evidence for the Use of Steroids in the Medical Intensive Care Unit
Jenkins, P., Cross, C., Abdo, T., Youness, H. A., & Keddissi, J. I. (2024) · Diagnostics · doi:10.3390/diagnostics14141565 · Cited by 9
Bruyn, L. D., Téblick, A., Oudenhove, T. V., Perre, S. V., Derese, I., Pauwels, L., Derde, S., Vlieger, G. D., den Berghe, G. V., & Langouche, L. (2024) · Critical Care · doi:10.1186/s13054-024-05079-8 · Cited by 8
“…frequently used in patients with acute respiratory distress syndrome (ARDS), to reduce pulmonary inflammation or as an adjunctive vasopressor therapy for patients with septic shock [38, 39], the mortality benefit of glucocorticoids across randomized controlled trials is inconsistent [20, 40–45].”
BackgroundThe Emperor Has No Clothes? Searching for Dysregulation in Sepsis
Alcock, J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7090247 · Cited by 9
“Published after the ADRENAL trial, the APROCCHSS trial studied 1241 patients with septic shock and reported a survival benefit for those receiving hydrocortisone and fludrocortisone [26].”
MethodVitamin C, Thiamine, and Steroids in the Sepsis Conquest: Replete to Defeat
Guirguis, E. H., Grace, Y., Maarsingh, H., Tran, T. C., & Tkachuk, E. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019851923 · Cited by 8
“Therapy with IV corticosteroids is currently included in The Surviving Sepsis Campaign Guidelines as adjunctive treatment for patients in septic shock, refractory to fluids and vasopressors however with the mortality benefits shown in the APROCCHSS study in 2018, it is reasonable for practitioners to initiate combinat…”
BackgroundMethodResultEffect of adjunctive corticosteroid on 28-day mortality in neutropenic patients with septic shock
Kang, J., Han, M., Hong, S., Lim, C., Koh, Y., & Huh, J. W. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03785-w · Cited by 8
Fujii, T., Belletti, A., Carr, A. C., Furukawa, T. A., Luethi, N., Putzu, A., Sartini, C., Salanti, G., Tsujimoto, Y., Udy, A. A., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-033458 · Cited by 8
Bonnin, S. S., Radosevich, J. J., Lee, Y. G., Feldman, J. P., & Barletta, J. F. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.12.001 · Cited by 8
Etomidate Is a First-Line Induction Agent in Critically Ill Patients
Lynde, G. C., & Jabaley, C. S. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003290 · Cited by 8
Current management of Gram-negative septic shock
Vincent, J., & Mongkolpun, W. (2018) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000492 · Cited by 9
Optimal approaches to preventing severe community-acquired pneumonia
Tanzella, G., Motos, A., Battaglini, D., Meli, A., & Torres, A. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1656531 · Cited by 8
“Today, corticosteroid use seems to reduce mortality in patients with sCAP [106] and also the treatment failure rate [107], while in patients with septic shock it reduces the treatment failure rate (including progression to acute respiratory distress syndrome) [108], duration of stay, ventilator-dependent days and time…”
BackgroundUpdates in the Management of Perioperative Vasoplegic Syndrome
Brennan, K. M., Bhutiani, M., Kingeter, M. A., & McEvoy, M. D. (2022) · Advances in Anesthesia · doi:10.1016/j.aan.2022.07.010 · Cited by 8
Glucocorticoid therapy for sepsis in the AI era: a survey on current and future approaches
Liang, C., Pan, S., Wu, W., Chen, F., Zhang, C., Zhou, C., Gao, Y., Ruan, X., Quan, S., Zhao, Q., et al. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.04.020 · Cited by 7
“Annane et al. [42,43], in studies conducted in 2006 and 2018, observed improved outcomes with low-dose hydrocortisone and fludrocortisone in certain patients.”
ResultLi, C., Zhao, K., Ren, Q., Chen, L., Zhang, Y., Wang, G., & Xie, K. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1485554 · Cited by 8
Abdominal Sepsis in Surgery and does this "Diagnosis" Really Exist? Effective Surgical Therapy
Hernández, J. L. G., Sánchez, M. A. G., Barrón, G. M., Suárez, I. A. L., & Cabello, J. D. J. U. (2025) · British journal of healthcare and medical research · doi:10.14738/bjhr.1202.18728 · Cited by 7
Venkatesh, B., Rey, D. A., Evans, D. M., Yao, L., Finfer, S. R., Bellomo, R., Silva, T. C., Cohen, J., Qiu, Y. L., Lucena, W. D. R., et al. (2025) · Critical Care and Resuscitation · doi:10.1016/j.ccrj.2025.100109 · Cited by 7
Hormone Therapy in Trauma Patients
Asehnoune, K., Vourc’h, M., & Roquilly, A. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2018.11.009 · Cited by 7
Self-citationKyriazopoulou, E., & Giamarellos‐Bourboulis, E. J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1589451 · Cited by 7
“Two RCTs have recently been published sheddingmore light to this controversy; the ADRENAL trial [52] and the APROCCHSS trial [53].”
BackgroundMetabolic resuscitation in pediatric sepsis: a narrative review
Schlapbach, L. J., de Oliveira, C. F., Raman, S., & de Souza, D. (2021) · Translational Pediatrics · doi:10.21037/tp-21-1 · Cited by 9
Choi, K., Park, J. E., Kim, A., Hwang, S., Bae, J., Shin, T. G., & Kim, K. (2022) · Clinical and Experimental Emergency Medicine · doi:10.15441/ceem.22.276 · Cited by 7
Maamar, A., Guillot, P., Joussellin, V., Delamaire, F., Painvin, B., Bichon, A., de Lajartre, O. B., Mauget, M., Lesouhaitier, M., Tadié, J., et al. (2023) · ERJ Open Research · doi:10.1183/23120541.00554-2022 · Cited by 7
“In cases of suspected or documented bacterial infection and septic shock, influenza patients received 50 mg per 6 hours of hydrocortisone plus 50 micrograms of fludrocortisone in association with norepinephrine [22].”
A novel vital sign pattern predicts sepsis-related myocardial injury mortality
Liu, W., Dai, J., Zhang, P., Ni, M., Zhang, Y., Fang, H., & Zhang, Z. (2024) · iScience · doi:10.1016/j.isci.2024.110787 · Cited by 7
Blythe, R. D., Cook, D., & Graves, N. (2018) · F1000Research · doi:10.12688/f1000research.14619.1 · Cited by 8
Barakakis, P. A., Palaiodimos, L., Sosa, D. F., Benes, L., Gulani, P., & Fein, D. G. (2019) · Avicenna Journal of Medicine · doi:10.4103/ajm.ajm_97_19 · Cited by 7
“…I 2 = 92.30%), data available from all included studies, [6,8-10] GI hemorrhage (OR, 1.05, CI, 0.77–1.42, I 2 = 0.00%), with patient data available from two RCTs, [6,8] or superinfection (OR, 0.95, CI, 0.64–1.42, I 2 = 21.38%), with patient data available from two RCTs [6,8] [Figures 4–8].”
InfluentialLi, J., Xie, M., Yu, Y., Tang, Z., Hang, C., & Li, C. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108660 · Cited by 7
Krieger, J. A., McGuire, F., Risa, E. L., Longino, A. A., Coppess, S. M., Riveros, T., Hebert, C., Town, J. A., Bhatraju, P. K., & Johnson, N. J. (2021) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12350 · Cited by 7
Machado‐Alba, J. E., Usma-Valencia, A. F., Sánchez-Ramírez, N., Valladales‐Restrepo, L. F., Machado‐Duque, M. E., & Gaviria‐Mendoza, A. (2021) · Drugs - Real World Outcomes · doi:10.1007/s40801-021-00241-y · Cited by 7
“Varying results have been reported by different studies, especially in mechanically ventilated patients [29, 30].”
BackgroundResultHammond, N. E., Kumar, A., Vijayaraghavan, B. K. T., Arabi, Y. M., Cohen, J., Tanna, G. L. D., Grattan, S., van Heerden, V., Joynt, G. M., Machado, F. S., et al. (2021) · Critical Care and Resuscitation · doi:10.51893/2021.2.s1 · Cited by 7
Wang, K., Yin, L., Song, Y., Zhang, M., Lu, Y., & Wang, S. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900221097193 · Cited by 7
“The use of corticosteroids may have mortality benefits in critically ill patients with septic shock but the results are mixed.(8,9) In 2017, Marik et al(10) conducted a small before-after retrospective study that showed mortality benefit of using ascorbic acid, together with hydrocortisone and thiamine (HAT) compared…”
BackgroundRagoonanan, D., Tran, N., Modi, V., & Nickelsen, P. M. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac169 · Cited by 8
Hydrocortisone Reduces 28-day Mortality in Septic Patients: A Systemic Review and Meta-analysis
Siddiqui, W. J., Iyer, P. S., Aftab, G. M., Zafrullah, F., Zain, M. A., Jethwani, K., Mazhar, R., Abdulsalam, U., Raza, A., Hanif, M. O., et al. (2019) · Cureus · doi:10.7759/cureus.4914 · Cited by 7
“septic shock) [12], and the trials with the highest mortality (French, APROCHSS) likely with the sickest patients, showed a mortality benefit [9,14].”
BackgroundMethodResultInfluentialAdding vitamin C to hydrocortisone lacks benefit in septic shock: a historical cohort study
Chang, K. L., Harbin, M., Shuster, C., Griesdale, D. E. G., Foster, D., Sweet, D. D., Wood, M. D., & Dhingra, V. K. (2020) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-020-01814-1 · Cited by 7
Circulating biomarkers to assess cardiovascular function in critically ill
van Lier, D. P. T., & Pickkers, P. (2021) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000829 · Cited by 9
Risk assessment, diagnosis, and treatment of cancer treatment-related adrenal insufficiency
Hayes, A. G., Rushworth, R. L., & Torpy, D. J. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2023009 · Cited by 7
“tality benefit from parenteral hydrocortisone and fludrocortisone in CIRCI, and reduced time on vasopressor support [122].”
BackgroundForceville, X., Laviolle, B., Gromadzińska, J., Boutten, A., Antwerpen, P. V., Plouvier, E., Annane, D., & Bellissant, É. (2022) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2022.127031 · Cited by 10
“It remains to date without specific treatment, at the exception of low dose steroids [9,10].”
BackgroundSelf-citationCirrhosis Management in the Intensive Care Unit
Smith, T. N., de Moraes, A. G., & Simonetto, D. A. (2023) · Seminars in Liver Disease · doi:10.1055/a-2015-1290 · Cited by 8
Heart rate and blood pressure chronomes during and after pregnancy.
Ayala, D. E., Hermida, R. C., Cornélissen, G., Brockway, B., & Franz Halberg, A. (1994) · PubMed · Cited by 7
Romiti, G. F., Corica, B., Raparelli, V., Basili, S., & Cangemi, R. (2020) · Nutrients · doi:10.3390/nu12061550 · Cited by 7
“The immunomodulatory effect of steroids has been postulated, and their use in the setting of intensive care has been widely studied, with conflicting results [14,15].”
BackgroundFluids or vasopressors for the initial resuscitation of septic shock
Macdonald, S., Peake, S. L., Corfield, A. R., & Delaney, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1069782 · Cited by 6
“The combination of hydrocortisone and fludrocortisone was found to reduce 90-day mortality (24).”
BackgroundWiss, A. L., Doepker, B. A., Hoyte, B., Olson, L. M., Disney, K. A., McLaughlin, E. M., Esguerra, V. G., & Elefritz, J. L. (2023) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2023.05.001 · Cited by 6
Li, Y., Wang, Y., Guo, J., & Zhang, D. (2024) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2024.05.001 · Cited by 6
Reevaluating vitamin C in sepsis and septic shock: a potential benefit in severe cases?
Alissa, A. S., Alrashed, M. A., Alshaya, A. I., Sulaiman, K. A. A., & Alharbi, S. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1476242 · Cited by 6
Chen, Y., Kuang, H., Zhu, Y., & Luo, X. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1457469 · Cited by 6
Li, J., LI, Z., Qian, J., Liao, W., & Xu, F. (2025) · Scientific Reports · doi:10.1038/s41598-025-99198-z · Cited by 6
“Continuous infusion of hydrocortisone effectively reduces fluctuations in blood sugar levels and avoids complications such as hypernatremia 11 .”
Fujishima, S. (2025) · Journal of Intensive Care · doi:10.1186/s40560-025-00809-8 · Cited by 6
Shah, A. M., Dave, S. B., Galvagno, S. M., George, K., Menne, A. R., Haase, D., McCormick, B. M., Rector, R. P., Dahi, S., Madathil, R. J., et al. (2021) · Membranes · doi:10.3390/membranes11050306 · Cited by 6
“If a patient began to develop signs of overt inflammatory response, a high dose of dexamethasone over 10 days was used [93].”
MethodBourdiol, A., & Roquilly, A. (2022) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1740606 · Cited by 6
Sacha, G. L., Chen, A. Y., Palm, N. M., Wang, X., Li, M., & Duggal, A. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900211037589 · Cited by 6
“This is contradictory to prior trials that included patients who were more critically ill and demonstrated a reduction in mortality with hydrocortisone use.(10,13) However, because of the significant differences in patient cohorts and the likely confounding by indication in the current study, comparing these two popul…”
MethodResultInfluentialAbrupt Discontinuation Versus Taper of Hydrocortisone in Patients With Septic Shock
Carabetta, S., Allen, B., Cannon, C., & Johnson, T. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221117156 · Cited by 6
Rivas, M., Motes, A., Ismail, A., Yang, S., Sotello, D., Arevalo, M., Vutthikraivit, W., Suchartlikitwong, S., Carrasco, C., IWUJI, K. C., et al. (2023) · SAGE Open Medicine · doi:10.1177/20503121221146907 · Cited by 6
A Narrative Review of Drug Therapy in Adult and Pediatric Cardiac Arrest
Jaeger, D., Marquez, A. M., Kosmopoulos, M., Gutiérrez, A., Gaisendrees, C., Orchard, D. A., Chouihed, T., & Yannopoulos, D. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2406163 · Cited by 6
Epidemiology of sepsis in a Japanese administrative database
Imaeda, T., Oami, T., Takahashi, N., Saito, D., Higashi, A., & Nakada, T. (2023) · Acute Medicine & Surgery · doi:10.1002/ams2.890 · Cited by 6
“51 Although the administration of steroids for sepsis remains a topic of controversy, it is plausible that specific patient cohorts may exhibit improved outcomes with such treatment.”
BackgroundDong, Y., Heng, G., Zhang, J., Shen, Y., Lan, Z., Wei, K., & Jin, W. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1276181 · Cited by 7
Therapeutic Role of HAT Therapy in Sepsis: A Systematic Review and Meta-Analysis
Saghafi, F., Moghadam, Z. B., Salehi‐Abargouei, A., Beigrezaei, S., Sohrevardi, S. M., Jamialahmadi, T., Sahebnasagh, A., & Sahebkar, A. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673245464231121094448 · Cited by 6
Enhancing acute inflammatory and sepsis treatment: superiority of membrane receptor blockade
Mun, S., Cho, E., Kim, H. K., Gil, W. J., & Yang, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424768 · Cited by 7
Targeting sepsis through inflammation and oxidative metabolism
Jacob, S., Jacob, S. A., & Thoppil, J. J. (2024) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v14.i1.101499 · Cited by 7
Immunoadsorption Techniques and Its Current Role in the Intensive Care Unit
Hamilton, P., Harris, R., & Mitra, S. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84890 · Cited by 8
Metadata
- Authors
- Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J.-P., Siami, S., Cariou, A., Forceville, X., Schwebel, C., Martin, C., Timsit, J.-F., Misset, B., Ali Benali, M., Colin, G., Souweine, B., Asehnoune, K., Mercier, E., Chimot, L., Charpentier, C., François, B., Boulain, T., Petitpas, F., Constantin, J.-M., Dhonneur, G., Baudin, F., Combes, A., Bohé, J., Loriferne, J.-F., Amathieu, R., Cook, F., Slama, M., Leroy, O., Capellier, G., Dargent, A., Hissem, T., Maxime, V., & Bellissant, E.
- Affiliations
- Inserm (FR)
- From Service de Médecine Intensive et Réanimation, Hôpital Raymond Poincaré, Garches (D.A., V.M.), Laboratory of Infection and Inflammation Unité 1173, University of Versailles Saint-Quentin-en-Yvelines, INSERM, Montigny-le-Bretonneux (D.A.), Service de Pharmacologie Clinique–Centre d’Investigation Clinique (CIC) INSERM 1414, Centre Hospitalier Universitaire (CHU) de Rennes–Université de Rennes 1, Hôpital Pontchaillou, Rennes (A.R., E.B.), Service de Réanimation Médicale (C.B.-B.) and Service...
- ORCID
- Annane, Djillali
- Renault, Alain
- Quenot, Jean-Pierre
- Siami, Shidasp
- Cariou, Alain
- Forceville, Xavier
- Schwebel, Carole
- Misset, Benoît
- Souweine, Bertrand
- Asehnoune, Karim
- François, Bruno
- Boulain, Thierry
- Constantin, Jean-Michel
- Combes, Alain
- Bohé, Julien
- Amathieu, Roland
- Cook, Fabrice
- Slama, Michel
- Capellier, Gilles
- Dargent, Auguste
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03
- Volume
- 378
- Issue
- 9
- Pages
- 809-818
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2794125559
- Cited by
- 939
- References
- 22
- Citations by year
- 2026: 107 · 2025: 104 · 2024: 97 · 2023: 115 · 2022: 101 · 2021: 98 · 2020: 121 · 2019: 123 · 2018: 70
- FWCI
- 80.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Funders
- Ministère des Affaires Sociales et de la Santé (Programme Hospitalier de Recherche Clinique / P 07)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- cortisol, fludrocortisone, drotrecogin alfa (activated), corticosteroid therapy, host response to infection, 90-day mortality, vasopressor-free days, organ failure, mechanical ventilation, intensive care unit discharge, sepsis treatment
- MeSH terms
- Simplified Acute Physiology Score, Aged, Anti-Inflammatory Agents, Cause of Death, Combined Modality Therapy, Double-Blind Method, Drug Therapy, Combination, Female, Fludrocortisone, Humans, Hydrocortisone, Male, Middle Aged, Recurrence, Respiration, Artificial, Shock, Septic, Survival Analysis, Treatment Outcome, Renal Replacement Therapy, Organ Dysfunction Scores
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.